Evidence map›Paper›PMID 37944053›Full record

Trial reportJNCI cancer spectrum2023

A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases.

Amit K Garg, Mike Hernandez, Pamela J Schlembach, John R Bowers, Mary F McAleer, Paul D Brown, Ramesh Gopal, Lee Wiederhold, Todd Swanson, Shalin J Shah and 6 more

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JNCI cancer spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Amit K GargDepartment of Radiation Oncology, Presbyterian Healthcare Services, Albuquerque, NM, USA.
Mike HernandezDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pamela J SchlembachDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John R BowersDepartment of Radiation Oncology, Presbyterian Healthcare Services, Albuquerque, NM, USA.
Mary F McAleerDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paul D BrownDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Ramesh GopalDepartment of Radiation Oncology, University of New Mexico, Albuquerque, NM, USA.
Lee WiederholdDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Todd SwansonDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shalin J ShahDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jing LiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sherise D FergusonDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nancy V PhilipDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lilybeth DeGraciaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elizabeth S BloomDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephen G ChunDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4324-8044
The University of Texas MD Anderson Cancer Center · USPresbyterian Healthcare Services · USMayo Clinic in Arizona · USUniversity of New Mexico · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer InstituteR50CA275822 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Stephen G Chun · 2023 to 2026
$347k
NCI NIH HHS P30 CA016672NCI NIH HHS R50 CA275822
6 · The paper itself

Abstract

Stereotactic radiation therapy yields high rates of local control for brain metastases, but patients in rural or suburban areas face geographic and socioeconomic barriers to its access. We conducted a phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases in an integrated academic satellite network for patients 18 years of age or older with 4 or fewer brain metastases. Dose was based on gross tumor volume: less than 3.0 cm, 27 Gy in 3 fractions and 3.0 to 3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients, with a median age of 68 years. Median intracranial progression-free survival was 7.1 months (95% confidence interval = 5.3 to not reached), and median survival was 7.2 months (95% confidence interval = 5.4 to not reached); there were no serious adverse events. Outcomes of this trial compare favorably with contemporary trials, and this treatment strategy provides opportunities to expand stereotactic radiation therapy access to underserved populations.

Indexed as

Brain NeoplasmsRadiosurgeryAdolescentAdultAgedHumansTreatment Outcome

Identifiers

PMID37944053
PMCPMC10715838
OpenAlexW4388515683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.